Due to the recent nitrosamine contamination, pharmaceutical industries face new challenges to analyse traces of impurities in their materials with mass spectrometry. New EMA and FDA regulations are requiring more stringent detection of these genotoxic impurities (GTIs) for products sold in their markets.
During this webinar, our experts will share their practical knowledge on nitrosamine detection and quantification. They will focus on the risks and challenges faced when dealing with nitrosamines and will discuss the separation and instrumentation for development laboratories and QC. This will be followed by an informative Q&A session.
Register now if you want to know:
• How to conform to new regulations
• Where are the risks with respect to nitrosamines
• How to perform trace analysis in your API and drug products
• What are the recommended MS technologies and how important is the role of chromatography